Literature DB >> 16028130

Protective immunity associated with a strong serological response to a Cryptosporidium-specific antigen group, in HIV-infected individuals.

Floyd J Frost1, Kristine Tollestrup, Gunther F Craun, Christopher K Fairley, Martha I Sinclair, Twila R Kunde.   

Abstract

This study assessed whether serological responses to Cryptosporidium antigens are associated with a reduced risk of diarrheal illness in cases of infection with human immunodeficiency virus (HIV). The association between serological responses to the Cryptosporidium 15/17-kDa and 27-kDa antigen groups and reported diarrheal illness was examined by use of data from a previously published study of cases of HIV infection. In immunosuppressed individuals, a strong serological response to the 27-kDa antigen group was associated with a reduced risk of diarrhea without weight loss. This finding suggests that acquired protective immunity to cryptosporidiosis may be important in controlling the burden of cryptosporidiosis in immunosuppressed individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028130     DOI: 10.1086/431681

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Systemic antibody responses to the immunodominant p23 antigen and p23 polymorphisms in children with cryptosporidiosis in Bangladesh.

Authors:  Anoli J Borad; Geneve M Allison; David Wang; Sabeena Ahmed; Mohammad M Karim; Anne V Kane; Joy Moy; Patricia L Hibberd; Sitara Swarna Rao Ajjampur; Gagandeep Kang; Stephen B Calderwood; Edward T Ryan; Elena Naumova; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 2.  Intestinal immune response to human Cryptosporidium sp. infection.

Authors:  Birte Pantenburg; Sara M Dann; Heuy-Ching Wang; Prema Robinson; Alejandro Castellanos-Gonzalez; Dorothy E Lewis; A Clinton White
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

Review 3.  Challenges in understanding the immunopathogenesis of Cryptosporidium infections in humans.

Authors:  R J Kothavade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

4.  Immune response of newborn BALB/c mice to Cryptosporidium infection.

Authors:  Nasser Ahmadian; Roghiyeh Pashaei-Asl; Masomeh Ahmadian; Mohammad Rahmati-Yamchi; Saed Shahabi; Hossein Vazini
Journal:  J Parasit Dis       Date:  2014-12-20

Review 5.  Human immune responses in cryptosporidiosis.

Authors:  Anoli Borad; Honorine Ward
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

6.  Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses.

Authors:  Jane W Wanyiri; Henry Kanyi; Samuel Maina; David E Wang; Aaron Steen; Paul Ngugi; Timothy Kamau; Tabitha Waithera; Roberta O'Connor; Kimani Gachuhi; Claire N Wamae; Mkaya Mwamburi; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

Review 7.  Giardia and Cryptosporidium and public health: the epidemiological scenario from the Italian perspective.

Authors:  Annunziata Giangaspero; Federica Berrilli; Olga Brandonisio
Journal:  Parasitol Res       Date:  2007-06-26       Impact factor: 2.289

8.  Antibody responses to Cryptosporidium antigen in HIV-positive patients in the Republic of Korea.

Authors:  Sang-Mee Guk; Jong-Yil Chai; Yung-Oh Shin; Min Seo
Journal:  Korean J Parasitol       Date:  2008-06       Impact factor: 1.341

9.  Identification and characterization of a new 34 kDa MORN motif-containing sporozoite surface-exposed protein, Cp-P34, unique to Cryptosporidium.

Authors:  Justyna J Jaskiewicz; Jacqueline M Tremblay; Saul Tzipori; Charles B Shoemaker
Journal:  Int J Parasitol       Date:  2021-03-25       Impact factor: 4.330

10.  Serum immunoglobulin G, M and A response to Cryptosporidium parvum in Cryptosporidium-HIV co-infected patients.

Authors:  Kirti Kaushik; Sumeeta Khurana; Ajay Wanchu; Nancy Malla
Journal:  BMC Infect Dis       Date:  2009-11-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.